Douglas Calder
Vermogen: 4 657 $ op 31-05-2026
Vermogen: 4 657 $ op 31-05-2026
Douglas W.
Calder is currently an Independent Director at Zevra Therapeutics, Inc. since 2023, a Director at BioFlorida, Inc. since 2019, a Director at Nextgennk since 2019, an Independent Director at Lunai Bioworks, Inc. since 2024, and a Member of the Society For Natural Immunity since 2018.
Former roles include Director-Investor Relations & Public Relations at Accentia Biopharmaceuticals, Inc. from 2012 to 2013, President & Director at Vycellix, Inc., VP-Strategic Planning & Capital Markets at BioVest International, Inc. from 2012 to 2013, Executive Vice President at Pulse Evolution Corp., President at VyGen-Bio, Inc., and Portfolio Manager at Dean Witter Reynolds, Inc. and Gruntal & Co. LLC.
Education includes undergraduate studies at Florida State University.
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
LUNAI BIOWORKS, INC. 0,03% | 10-04-2026 | 1.512 ( 0,03% ) | 4 657 $ | 31-05-2026 |
| 06-04-2026 | 0 ( -.--% ) | - $ | 31-05-2026 |
| Bedrijven | Functie | Begin |
|---|---|---|
| ZEVRA THERAPEUTICS, INC. | Directeur/Bestuurslid | 25-04-2023 |
| LUNAI BIOWORKS INC. | Directeur/Bestuurslid | 14-10-2024 |
Nextgennk | Directeur/Bestuurslid | 01-06-2019 |
BioFlorida, Inc.
BioFlorida, Inc. Miscellaneous Commercial ServicesCommercial Services Provides infrastructure to exchange information and ideas through industry specific programming, education, networking and legislative initiatives. | Directeur/Bestuurslid | 01-01-2019 |
| Bedrijven | Functie | Einde |
|---|---|---|
BioVest International, Inc.
BioVest International, Inc. Medical SpecialtiesHealth Technology Develops and commercializes personalized therapeutic cancer vaccine for the treatment of B-cell blood cancers | Investor Relations Contact | 16-07-2013 |
| ACCENTIA BIOPHARMACEUTICALS INC | Investor Relations Contact | 04-03-2013 |
Dean Witter Reynolds, Inc.
Dean Witter Reynolds, Inc. Investment ManagersFinance Investment management | Corporate Officer/Principal | - |
Gruntal & Co. LLC
Gruntal & Co. LLC General GovernmentGovernment Provides financial services | Corporate Officer/Principal | - |
VyGen-Bio, Inc.
VyGen-Bio, Inc. BiotechnologyHealth Technology Develops cell & gene therapies and treatments for cancer | President | - |
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
| Bedrijven in privébezit | 12 |
|---|---|
BioVest International, Inc.
BioVest International, Inc. Medical SpecialtiesHealth Technology Develops and commercializes personalized therapeutic cancer vaccine for the treatment of B-cell blood cancers | Health Technology |
Accentia Biopharmaceuticals, Inc.
Accentia Biopharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops and markets biopharmaceuticals | Health Technology |
Zevra Therapeutics, Inc.
Zevra Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops, manufactures and markets proprietary prodrugs | Health Technology |
Lunai Bioworks, Inc.
Lunai Bioworks, Inc. BiotechnologyHealth Technology Operates as preclinical stage biotechnology company developing technologies and therapies for HIV, HBV and cancer | Health Technology |
Pulse Evolution Corp.
Pulse Evolution Corp. Information Technology ServicesTechnology Services Produces photorealistic digital humans and provides digital production | Technology Services |
Dean Witter Reynolds, Inc.
Dean Witter Reynolds, Inc. Investment ManagersFinance Investment management | Finance |
Gruntal & Co. LLC
Gruntal & Co. LLC General GovernmentGovernment Provides financial services | Government |
Florida State University
Florida State University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
BioFlorida, Inc.
BioFlorida, Inc. Miscellaneous Commercial ServicesCommercial Services Provides infrastructure to exchange information and ideas through industry specific programming, education, networking and legislative initiatives. | Commercial Services |
Vycellix, Inc.
Vycellix, Inc. BiotechnologyHealth Technology Engages in the development of transformational platform technologies for cell & gene-based therapies | Health Technology |
Nextgennk | |
VyGen-Bio, Inc.
VyGen-Bio, Inc. BiotechnologyHealth Technology Develops cell & gene therapies and treatments for cancer | Health Technology |
Kies jouw editie
Alle financiële informatie op nationaal niveau